Work

A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps3095

Authors: Howard Kaufman, Jiafeng Wang, Brendan D. Curti, Joseph Clark, Marc S. Ernstoff, Ann Silk, Janice M. Mehnert, Andrew Zloza, Joe Shih, David F. McDermott

Institutions: Rush University Medical Center, Rutgers Cancer Institute, Providence Portland Medical Center, Loyola University Medical Center, Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, Beth Israel Deaconess Medical Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2600462446

Cites:

Cited by: 1

Related to: 10